True, President Joe Biden is proposing the largest-ever funding increase for NIH, with a substantial percentage of funds going toward cancer.
President Joe Biden’s proposed Advanced Research Projects Agency-Health would be a welcome partner to NCI—particularly in conducting large, collaborative clinical investigations, NCI Director Ned Sharpless said.“I think having ARPA-H as part of the NIH is good for the NCI,” Sharpless said April 11 in his remarks at the annual meeting of the American Association for Cancer Research. “How this would fit with the ongoing efforts in cancer at the NCI is still something to work out.”
NCI has established a program at Frederick National Laboratory to manufacture CAR T-cell therapies for multicenter clinical trials.
Pandemic notwithstanding, NCI is on track to reach the 15th percentile for the payline by 2025—a goal set by institute Director Ned Sharpless in response to a deluge of grant applications.
NCI has joined a nationwide initiative to increase the number of underrepresented minority faculty at NIH-funded cancer hospitals.
NCI plans to mark the 50th anniversary of the National Cancer Act of 1971 with an effort to build a coalition of support for cancer research, including raising the payline to 15% by 2025.
The COVID-19 pandemic will likely cause at least 10,000 excess deaths from breast cancer and colorectal cancer over the next 10 years in the United States.
Delayed cancer diagnoses, deferred care, and postponed surgeries amid the COVID-19 pandemic will adversely impact cancer outcomes, which may show up as an increase in cancer mortality in the next few years, said NCI Director Ned Sharpless.
In spite of disruptions caused by the coronavirus pandemic, NCI continues to review grants, disburse funds, and support extramural research, said NCI Director Ned Sharpless.
The pace of innovation in oncology has made U.S. cancer researchers prime targets for foreign state-sponsored programs aimed at diverting intellectual property.
